Bayer’s Stock Holds Steady Even as Tariff Risks and a Legal Landmark Loom
Published on 06/25/2026 at 05:15 | Redaktion boerse-global.de
Bayer investors are bracing for a pivotal stretch that pits fresh operational momentum against a thicket of US trade and legal threats. The pharmaceutical and agriculture group has seen its shares climb more than 50% over the past twelve months, but two headline risks — a potential wave of American tariffs on German drugs and a Supreme Court ruling on glyphosate — are now converging in a way that could test that resilience.
The US Trade Representative’s office launched a formal Section 301 investigation into German pharmaceutical pricing policy on 25 June 2026, opening a 45-day public comment period. At the heart of the probe are two Berlin measures: a 9% price reduction applied to confidential drug prices, and a planned law — the GKV-Beitragssatzstabilisierungsgesetz — that would impose a mandatory manufacturer rebate on patented medicines beginning in 2027. The rebate starts at 3.5% and is scheduled to climb to 20% by 2030. Washington has branded this a “significant step backward” and is threatening retaliatory tariffs that would hit Bayer hard, given the group’s heavy reliance on the US market for its pharmaceuticals business.
The tariff timeline is aggressive. From 31 July 2026, select pharma companies will face initial duties; further firms will be added by the end of September. Even if a manufacturer shifts production to the US, the plan envisages a 20% tariff that rises to 100% after four years. Trade officials point to a recent agreement with the United Kingdom, which secures tariff-free access for British drugmakers until early 2029 in exchange for higher National Health Service prices for new treatments. Germany’s health minister, Nina Warken, has rejected that model, citing the strained finances of the country’s statutory health insurers.
Should investors sell immediately? Or is it worth buying Bayer?
Compounding the trade uncertainty is a Supreme Court ruling expected within days in the case of Durnell v. Bayer. The justices are weighing whether state law can override a federal safety clearance from the Environmental Protection Agency for glyphosate-based herbicides. A victory for Bayer would extinguish roughly 65,000 pending claims; a defeat would keep the litigation mill running and add to the €5 billion in legal costs the company expects to book this year. That burden has already slashed free cash flow, with management forecasting an outflow of up to €2.5 billion in 2026.
Amid the noise, Bayer racked up a modest operational win in mid-June when the US Food and Drug Administration approved Ambelvist, a new contrast agent for MRI scans. The drug makes lesions in the central nervous system visible at a dose of just 0.04 mmol gadolinium per kilogram of body weight — roughly 60% less than conventional agents. Ambelvist already has approval in Japan, and the FDA green light gives Bayer a fresh commercial lever in the US at a time when its pipeline is closely watched.
The stock has so far shrugged off the gathering headwinds. Bayer closed at €39.89 on Wednesday, comfortably above its 200-day moving average of €36.39 and within 20% of its 52-week high near €50. The 12-month gain stands at over 51%. Yet the path ahead is littered with catalysts: the Supreme Court could rule on Durnell before the end of this week; the first tranche of US tariffs kicks in on 31 July; written comments in the Section 301 probe are due by 10 August; and a public hearing at the US Trade Representative’s office is scheduled for 22 September. How Bayer’s share price navigates that gauntlet will determine whether the old highs come back into reach or recede further into the distance.
Ad
Bayer Stock: New Analysis - 25 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
